Moreover, the E2F score serves as a predictive biomarker of response to neoadjuvant chemotherapy in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients (Oshi et al., 2020). The gene discussed is ESR1; the disease is breast carcinoma.